This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Matthew C. Kapusta net worth and biography

Matthew Kapusta Biography and Net Worth

CEO of uniQure

Mr. Matthew Kapusta has been Chief Executive Officer of uniQure since December 2016, and currently serves on the Company’s Board of Directors. Mr. Kapusta also has served as our Chief Financial Officer since joining uniQure in January 2015.

Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics from 2011 to 2014, responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance for Smith & Nephew Orthopaedics. Mr. Kapusta's career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber.

Mr. Kapusta holds a Master of Business Administration from New York University's Stern School of Business and a bachelor’s degree in Business Administration from University of Michigan's Ross School of Business. He earned his Certified Public Accountant license in 1996 while at Ernst & Young.

What is Matthew C. Kapusta's net worth?: The estimated net worth of Matthew C. Kapusta is at least $10.15 million as of December 9th, 2024. Mr. Kapusta owns 597,915 shares of uniQure stock worth more than $10,152,597 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Kapusta may own. Additionally, Mr. Kapusta receives a salary of $1,020,000.00 as CEO at uniQure. Learn More about Matthew C. Kapusta's net worth.
How old is Matthew C. Kapusta?: Mr. Kapusta is currently 52 years old. There are 3 older executives and no younger executives at uniQure. Learn More on Matthew C. Kapusta's age.
What is Matthew C. Kapusta's salary?: As the CEO of uniQure, Mr. Kapusta earns $1,020,000.00 per year. Learn More on Matthew C. Kapusta's salary.
How do I contact Matthew C. Kapusta?: The corporate mailing address for Mr. Kapusta and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Matthew C. Kapusta's contact information.
Has Matthew C. Kapusta been buying or selling shares of uniQure?: In the last ninety days, Matthew C. Kapusta has sold $26,079.34 of uniQure stock. Most recently, Matthew C. Kapusta sold 3,418 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a transaction totalling $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company's stock, valued at $4,562,091.45. Learn More on Matthew C. Kapusta's trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 66,928 shares worth more than $421,017.91. The most recent insider tranaction occured on December, 9th when CEO Matthew C Kapusta sold 3,418 shares worth more than $26,079.34. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 12/9/2024.

Matthew C. Kapusta Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Sell	3,418	$7.63	$26,079.34	597,915
2/26/2024	Sell	27,904	$6.35	$177,190.40	440,839
3/7/2023	Sell	2,521	$21.39	$53,924.19	468,743
12/9/2022	Sell	6,648	$22.44	$149,181.12	368,481
2/28/2022	Sell	10,195	$16.70	$170,256.50
1/26/2022	Sell	10,901	$18.10	$197,308.10
7/14/2021	Sell	1,000	$27.77	$27,770.00
6/16/2021	Sell	3,450	$34.62	$119,439.00	262,470
5/12/2021	Sell	2,250	$32.29	$72,652.50	263,927
4/14/2021	Sell	5,350	$35.24	$188,534.00	267,895
3/17/2021	Sell	2,250	$33.16	$74,610.00	271,989
1/28/2021	Sell	31,499	$36.63	$1,153,808.37	227,622
12/16/2020	Sell	12,501	$48.41	$605,173.41	277,738
11/18/2020	Sell	10,313	$43.69	$450,574.97	283,780
10/14/2020	Sell	5,250	$35.86	$188,265.00	280,864
9/16/2020	Sell	7,500	$40.66	$304,950.00	288,062
8/25/2020	Sell	300	$40.27	$12,081.00	293,314
8/19/2020	Sell	4,300	$39.11	$168,173.00	294,764
7/22/2020	Sell	5,626	$42.31	$238,036.06	298,525
6/17/2020	Sell	7,501	$66.04	$495,366.04	307,332
4/22/2020	Sell	9,376	$56.87	$533,213.12	327,918
2/19/2020	Sell	7,501	$64.56	$484,264.56	290,654
1/31/2020	Sell	3,872	$57.98	$224,498.56	310,979
1/29/2020	Sell	23,583	$61.94	$1,460,731.02	310,979
1/27/2020	Sell	28,289	$65.55	$1,854,343.95	366,075
12/18/2019	Sell	7,540	$70.09	$528,478.60	374,991
11/20/2019	Sell	8,000	$53.74	$429,920.00	372,352
10/23/2019	Sell	8,000	$43.22	$345,760.00	378,836
9/18/2019	Sell	8,000	$47.31	$378,480.00
8/21/2019	Sell	8,000	$56.48	$451,840.00	391,230
7/17/2019	Sell	8,000	$71.45	$571,600.00	404,839
6/19/2019	Sell	8,000	$77.45	$619,600.00	409,407
5/15/2019	Sell	8,000	$58.38	$467,040.00	421,730
3/14/2019	Sell	67,376	$63.96	$4,309,368.96
1/28/2019	Sell	19,085	$31.42	$599,650.70	490,028
3/15/2018	Sell	39,169	$21.72	$850,750.68	439,764
1/4/2018	Sell	21,690	$19.87	$430,980.30

Matthew C. Kapusta Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $16.98

$15.35

$17.58

50 Day Range

MA: $8.13

$5.56

$17.40

2 Week Range

Now: $16.98

$3.73

$17.71

Volume

2,053,596 shs

Average Volume

1,659,723 shs

Market Capitalization

$827.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Matthew Kapusta Biography and Net Worth

What is Matthew C. Kapusta's net worth?

How old is Matthew C. Kapusta?

What is Matthew C. Kapusta's salary?

How do I contact Matthew C. Kapusta?

Has Matthew C. Kapusta been buying or selling shares of uniQure?

Who are uniQure's active insiders?

Are insiders buying or selling shares of uniQure?